Targets › PIK3R1
5 programs from 5 companies in 18 trials: 9 Phase 2, 7 Phase 1, 2 Phase 3; Oncology, Infectious disease, Other; next expected readout Dec 2026.
Binds to activated (phosphorylated) protein-Tyr kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues. (UniProt, P27986)
Open in Phaseline: the race on PIK3R1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Celcuity | Gedatolisib Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor | MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CA | Phase 3 | Breast Cancer; mCRPC (Metastatic Castration-resistant Prostate Cancer); Endometrial Cancer; TNBC - Triple-Negative Breast Cancer | Dec 2026 |
| National Cancer Institute (NCI) | Taselisib (GDC-0032) PI3-kinase class I inhibitor | PIK3R1, PIK3CB, PIK3CG, PIK3CA, PIK3R2 | Phase 2 | Advanced Lymphoma | Mar 2027 |
| Restorbio | Dactolisib (BEZ235) Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor | MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CA | Phase 2 | Respiratory Tract Infections; Covid19 | – |
| Eli Lilly | Samotolisib (LY3023414) Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor | MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CA | Phase 1 | Breast Neoplasms; Endometrial Cancer | Dec 2026 |
| Sovargen | Paxalisib (SVG103) PI3-kinase class I inhibitor | PIK3R1, PIK3CB, PIK3CG, PIK3CA, PIK3R2 | Phase 1 | Focal Cortical Dysplasia; Primary Central Nervous System Lymphoma; Glioblastoma; CDK Gene Mutation … | Feb 2027 |
Breast Cancer (2) Endometrial Cancer (2) Respiratory Tract Infections (1) Covid19 (1) mCRPC (Metastatic Castration-resistant Prostate Cancer) (1) TNBC - Triple-Negative Breast Cancer (1) Advanced Lymphoma (1) Breast Neoplasms (1) Focal Cortical Dysplasia (1) Primary Central Nervous System Lymphoma (1) Glioblastoma (1) CDK Gene Mutation (1)
small molecule (4), mixed (1)
Restorbio (1) Celcuity (1) National Cancer Institute (NCI) (1) Eli Lilly (1) Sovargen (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.